Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. (August 2011)

• Record Type: Journal Article
• Authors: Jacobs, Robert T; Plattner, Jacob J; Nare, Bakela; Wring, Stephen A; Chen, Daitao; Freund, Yvonne; Gaukel, Eric G; Orr, Matthew D; Perales, Joe B; Jenks, Matthew; Noe, Robert A; Sligar, Jessica M; Zhang, Yong-Kang; Bacchi, Cyrus J; Yarlett, Nigel; Don, Robert
• Is Part Of: Future medicinal chemistry. Volume 3:Number 10(2011)
• Page Start: 1259
• Page End: 1278
• Publication Date: 2011-08
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc.11.80
• Languages: English
• ISSNs: 1756-8919

Abstract

Human African trypanosomiasis, caused by the kinetoplastid parasite Trypanosoma brucei, affects thousands of people across sub-Saharan Africa, and is fatal if left untreated. Treatment options for this disease, particularly stage 2 disease, which occurs after parasites have infected brain tissue, are limited due to inadequate efficacy, toxicity and the complexity of treatment regimens. We have discovered and optimized a series of benzoxaborole-6-carboxamides to provide trypanocidal compounds that are orally active in murine models of human African trypanosomiasis. A key feature of this series is the presence of a boron atom in the heterocyclic core structure, which is essential to the observed trypanocidal activity. We also report the in vivo pharmacokinetic properties of lead compounds from the series and selection of SCYX-7158 as a preclinical candidate.